Turn­ing Point tracks an im­pres­sive ORR rate in NSCLC — but shares skid low­er on sec­ond look

CHICA­GO — Fresh off of a $166 mil­lion IPO raise, Turn­ing Point Ther­a­peu­tics $TP­TX joined the open­ing-day fes­tiv­i­ties at AS­CO with an up­date on their lead drug re­potrec­tinib — which they plan to pitch for an ear­ly ap­proval for ROS1+ ad­vanced non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER